Want to see HK:3839 full AI Analyst Report?
Top Page
Chia Tai Enterprises International
(3839)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$9.50
▲(12.56% Upside)
Action:Downgraded
Date:08/27/26
The score is primarily supported by improved financial performance (strong revenue rebound, better margins/returns, and low leverage) and a reasonable P/E valuation. These positives are tempered by only neutral-to-weak near-term technical signals (negative MACD, below short-term moving averages) and the company’s history of margin compression and uneven cash generation.
Positive Factors
Strong revenue rebound
The substantial 2025 revenue rebound indicates renewed demand and operating traction across the animal-health and agribusiness value chain. If sustained, greater scale can improve fixed-cost absorption and strengthen the company’s distribution reach.
Negative Factors
Gross margin compression
The sustained gap between current and earlier gross margins suggests pricing pressure, higher input costs, or a less favorable product mix. This weakens the durability of earnings and could limit profit growth even when revenue expands.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue rebound
The substantial 2025 revenue rebound indicates renewed demand and operating traction across the animal-health and agribusiness value chain. If sustained, greater scale can improve fixed-cost absorption and strengthen the company’s distribution reach.
Read all positive factors
Chia Tai Enterprises International (3839) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.18B
Dividend YieldN/A
Average Volume (3M)16.81K
Price to Earnings (P/E)11.6
Beta (1Y)1.44
Revenue Growth-18.70%
EPS Growth-5.97%
CountryHK
Employees1,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.10
Shares Outstanding240,718,300
10 Day Avg. Volume9,372
30 Day Avg. Volume16,807
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.85
Price to Sales (P/S)0.44
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chia Tai Enterprises International Business Overview & Revenue Model
Company Description
Chia Tai Enterprises International Limited primarily produces and distributes chlortetracycline (CTC) and related goods. Its extensive international reach covers Mainland China, the Asia Pacific region, the Americas, and Europe. The company's oper...
How the Company Makes Money
The company makes money primarily by selling and distributing animal health and related agribusiness products and services. Key revenue streams typically include: (1) product sales to farms, distributors, and veterinary channels (e.g., animal heal...
Chia Tai Enterprises International Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 424.03M | 536.71M | 307.75M | 173.98M | 159.24M | 142.41M |
| Gross Profit | 70.39M | 77.55M | 48.93M | 30.18M | 39.19M | 34.76M |
| EBITDA | 34.66M | 48.28M | 17.51M | 11.29M | 5.17M | 12.38M |
| Net Income | 24.44M | 32.10M | 11.17M | 2.55M | -6.68M | 19.56M |
Balance Sheet | ||||||
| Total Assets | 505.27M | 461.60M | 422.21M | 377.37M | 350.58M | 365.22M |
| Cash, Cash Equivalents and Short-Term Investments | 37.25M | 39.83M | 32.38M | 37.61M | 30.86M | 31.09M |
| Total Debt | 75.56M | 47.87M | 69.17M | 78.17M | 49.10M | 42.61M |
| Total Liabilities | 179.05M | 153.76M | 161.70M | 125.36M | 94.83M | 81.69M |
| Stockholders Equity | 293.73M | 277.11M | 234.77M | 228.43M | 230.85M | 253.06M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 28.04M | -2.56M | -27.17M | -10.38M | -28.46M |
| Operating Cash Flow | 0.00 | 34.33M | 11.29M | -16.06M | 5.63M | -10.91M |
| Investing Cash Flow | 0.00 | -2.79M | -9.27M | -7.14M | -15.64M | -9.84M |
| Financing Cash Flow | 0.00 | -24.38M | -7.07M | 30.23M | 10.38M | 19.36M |
Chia Tai Enterprises International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$16.55B | 25.92 | 3.09% | 3.29% | -12.86% | -83.10% | |
65 Neutral | HK$2.18B | 11.57 | 8.74% | ― | -18.70% | -5.97% | |
65 Neutral | HK$727.21M | 4.86 | 7.52% | 2.92% | 7.05% | 22.46% | |
60 Neutral | HK$17.25B | 15.23 | 6.61% | 3.21% | 7.35% | -45.49% | |
53 Neutral | HK$6.72B | -5.48 | -4.98% | 0.26% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$339.89M | 84.72 | 0.34% | 7.50% | -8.30% | -44.44% |
* Healthcare Sector Average
HK:3839
Chia Tai Enterprises International
8.69
2.43
38.74%
HK:3933
The United Laboratories International Holdings
8.36
-8.68
-50.96%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.35
-0.82
-37.73%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.04
-12.86%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.23
-0.92
-42.74%
HK:0512
Grand Pharmaceutical Group Limited
4.91
-3.77
-43.43%
Chia Tai Enterprises International Corporate Events
CPBIO renews HOEL supply deal and inks new CPF India agreement as connected transactions
Aug 11, 2026
CPBIO Holding Company Limited has entered into a new 2026 Master HOEL Purchase Agreement to continue supplying CPBIO products to the HOEL Group beyond the expiry of the existing 2023 agreement on 31 December 2026, largely on the same terms, includ...
CPBIO posts lower interim profit as revenue drops in first half of 2026
Aug 11, 2026
CPBIO Holding Company Limited reported unaudited revenue of US$211.4 million for the six months ended 30 June 2026, down from US$323.3 million a year earlier, with gross profit declining to US$34.7 million and net profit attributable to shareholde...
CPBIO Sets August Board Meeting to Approve Interim Results and Consider Dividend
Jul 28, 2026
CPBIO Holding Company Limited has scheduled a board meeting for 11 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend, signaling potentia...
CPBIO warns of sharply lower first-half profit as China animal farming slows
Jul 22, 2026
CPBIO Holding Company Limited has warned that its consolidated profit attributable to shareholders for the first half of 2026 is expected to drop to about US$9.5 million from US$17.0 million a year earlier. The company attributes the decline mainl...
CPBIO Holding Company Launches Comprehensive Rebrand on Hong Kong Listing
Jul 20, 2026
CPBIO Holding Company Limited has formally changed its English name from Chia Tai Enterprises International Limited to CPBIO Holding Company Limited, and its Chinese name to 正大生物控股有限公&...
Chia Tai Enterprises Wins Full Shareholder Backing at AGM, Approves Name Change and Capital Mandates
Jun 9, 2026
Chia Tai Enterprises International Limited secured strong shareholder backing at its 9 June 2026 annual general meeting in Hong Kong, where all resolutions were approved by poll. Shareholders adopted the 2025 audited accounts, re-elected five dire...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.